



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/528,974	First Named Inventor: Paul Murray
371 Filing Date: 03/23/2005	Attorney Docket No.: 100835-1P US
Examiner: Shameem, Golam M	Group Art Unit : 1626
Customer No.: 44992	Confirmation No.: 1465
Title: Process And Intermediates For The Preparation Of The Thienopyrrole Derivatives	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This is a response to an Office Action dated 09/11/2007, in which the Examiner requires Election/Restriction of the claims of this application. This response is filed within the one-month shortened statutory period for response as set out in the aforesaid Action.

Applicants hereby elect Group I: Claims 1-4 “drawn to processes for preparing a compound of formula I, classified in class 548 and several subclasses” without traverse.

Applicants request that the Examiner considers combining Group V into Group I. Applicants believe that the invention of Group V shares the requisite unifying inventive concept because the compounds of formula (I) and formula (XII) share substantial structural similarity and the compounds of formula (I) are intermediates for the compounds of formula (XII). Applicants therefore believe that searching Claims 1-4 and claim 11 would not be an undue burden for the Examiner.

Applicants elect the product of Example 1, methyl 2 chloro-6H-thieno[2,3-b]pyrrole-5-carboxylate, as the single species. Claims 1-4 read onto this compound.

Applicants respectfully request that this application be promptly examined on the merits.

Applicants reserve right to prosecute any un-elected subject matter in a timely filed divisional application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Application No. 10/528,974  
Amendment Dated 11<sup>th</sup> October 2007  
Reply to Office Action of 11<sup>th</sup> September 2007

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100835-1P US.

Respectfully submitted,  
/Lucy Padget/

---

Name: Lucy Padget  
Dated: October 11, 2007  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451